Who Can Act as a Sponsor under the New Zealand Medical Device Rules

1. Key takeaways

Regulatory information verified as of 29 October 2026. The sponsor is the only entity centrally accountable in the New Zealand medical device system, yet no qualification certificate exists for this role. Whether an entity can act as a sponsor depends on two questions: whether it exports or arranges export, imports or arranges import, or manufactures or arranges manufacture of the device in New Zealand; and whether it does so merely on behalf of another New Zealand resident or person carrying on business in New Zealand, in which case it is excluded.

Reg 3 of the Medicines (Database of Medical Devices) Regulations 2003 (SR 2003/325) works this way: paragraph (a) defines sponsors through three parallel scenarios, paragraph (b) excludes agents. Medsafe’s device definition page (1Definition.asp, revised 15 January 2015) turns this into an applicable test: A sponsor must have a presence in New Zealand. Organisations without a New Zealand presence cannot be sponsors.

The direct conclusion: overseas manufacturers cannot be the notifying entity in WAND (Web Assisted Notification of Devices). Where an overseas company supplies New Zealand institutions directly, Medsafe states in writing that the importer is the legal sponsor. The most frequent misjudgement: an overseas parent wishing to notify WAND in its own name; that path has no legal entry point.

A second misjudgement sits downstream: a sponsor is not a person or organisation that buys devices from a New Zealand sponsor and on-sells them in New Zealand. Wholesalers, distributors and hospital purchasers bear no notification duty unless they are the importer.

• Sponsor status flows from exporting, importing or manufacturing, or arranging those acts, under reg 3(a).
• Entities acting merely on behalf of a New Zealand resident or business are excluded by reg 3(b).
• Medsafe requires a New Zealand presence; overseas manufacturers cannot notify WAND.
• The importer is the legal sponsor for direct overseas supply.
• Downstream resellers and hospital purchasers are not sponsors.

2. Legal basis

The instruments relevant to sponsor eligibility are set out below.

3. Expert insights

Insight 1: the reg 3(b) exclusion is the only provision that can legitimately remove the need for one sponsor. Reg 3(b) excludes persons acting on behalf of another who is, at the time of export, import, manufacture or the arrangement, a New Zealand resident or in business in New Zealand. Medsafe’s reading: a sponsor may appoint an agent for import and distribution, but responsibility remains with the sponsor, not the agent. The value lies in group design: if an overseas parent’s New Zealand subsidiary arranges import while a logistics firm clears the goods, the firm is not a second sponsor. The agency relationship must be clear and provable; if the contracting party, bill of lading consignee, invoice title and WAND sponsor name diverge, reg 3(b) is hard to invoke in a dispute.

Insight 2: the statutory evidence of local presence is the single reg 5(1)(b)(i) field. Reg 5(1)(b)(i) requires the address of the sponsor’s registered office or principal place of business in New Zealand; an entity with neither cannot even complete the field. Medsafe’s wording matches: registered business or principal place of business in New Zealand. GRZAN adds one caution: whether a post office box or virtual office satisfies “principal place of business” is untested in the regulations (practical estimate); the risk arises at enforcement — the s 38 notice goes to the importer or manufacturer, and a sponsor who cannot receive it or produce evidence within 45 days bears the consequences alone.

Insight 3: Medsafe’s example lists have a wider boundary than expected. Medsafe lists 6 categories of sponsors, including a New Zealand hospital importing directly from an overseas manufacturer; a health professional importing a small quantity once, keeping one device and selling the rest; a New Zealand entity engaged in parallel importing; one repackaging devices into first aid kits for resale; and one having a third party manufacture kits to its specification. Only 2 negative examples exist: an overseas company supplying New Zealand institutions directly (the importer is the sponsor), and organisations or persons buying devices from a sponsor or devices supplied by a sponsor. No qualification, licence or scale threshold applies, and commercial import is not distinguished from institutional self-use: once an import occurs, the duty arises. Parallel importing being listed separately shows each import route for the same brand generates its own sponsor.

Insight 4: sponsor responsibilities are cumulative; the fine is only the smallest part. Medsafe summarises 7 responsibilities: s 38 safety, reg 6 notification, 10 working-day correction (reg 8), distribution records, immediate recall and corrective-action notification, labelling and advertising compliance. Breaches of reg 6, 8, 9 or 10 are punishable on conviction under reg 14 by a fine not exceeding NZ$500, often misread as a low cost of non-compliance. The real exposure is twofold: s 38(8) punishes selling before the safety evidence requirement is met with up to 6 months imprisonment or a fine not exceeding NZ$5,000; and s 80 makes sale prosecutions strict liability: intent need not be proved, and the no-intent plus all-reasonable-steps defence must be notified in writing to the prosecutor within 7 days of service of the summons, or it is inadmissible. Under s 79, when a body corporate is convicted, every director and every person involved in management may, in specified circumstances, commit the same offence.

4. Practical recommendations

• Confirm who is importing first, not who wants to be sponsor. GRZAN works backwards from trade documents: only when bill of lading consignee, import declaration entity and purchase contract signatory all point to the same New Zealand entity is the sponsor identity locked; otherwise the party actually arranging the import prevails.
• Overseas manufacturers should never notify WAND in their own name. Reg 3’s local presence requirement and Medsafe’s wording jointly exclude that path; GRZAN typically fixes sponsor identity, information duties and changeover arrangements in the distribution agreement.
• Write the “not a sponsor” scenarios into internal procedures. Downstream distributors and hospital purchasers often assume notification duties, causing duplicates or omissions; GRZAN’s client procedures include a reg 3(b) exclusion section with a decision flowchart.
• Design group structures around reg 3(b). If one New Zealand entity is to carry sponsor responsibility, it should arrange the import while other entities act as documented agents — avoiding multiple sponsors.
• Treat the 45-day window in s 38 as a hard constraint. The safety evidence duty can be triggered at any time; hold a retrievable technical documentation package before the first notification is completed.

5. Verification checklist

• □ Confirmed the sponsor has a registered office or principal place of business address in New Zealand for reg 5(1)(b)(i)
• □ Confirmed the entity falls within one of the three reg 3(a) scenarios (export, import, manufacture or arranging manufacture)
• □ Confirmed the entity is not excluded by reg 3(b), or its agency role is documented in writing
• □ Confirmed the overseas parent has not filed WAND in its own name
• □ Confirmed downstream distributors and hospital purchasers are not registered as sponsors
• □ Locked the start point of the 30 working-day notification period (reg 6)
• □ Documented internal procedures covering reg 5, reg 6, reg 8 and reg 9
• □ Prepared a retrievable technical package for the 45-day s 38 duty
• □ Confirmed directors know the s 79 / s 80 liability allocation and the 7-day notice requirement

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the New Zealand market. Our team coordinates New Zealand sponsor arrangements, import requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com